# Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

> **NCT05574504** · PHASE2 · WITHDRAWN · sponsor: **AdventHealth**

## Conditions studied

- Metastatic Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin

## Key facts

- **NCT ID:** NCT05574504
- **Lead sponsor:** AdventHealth
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-08
- **Primary completion:** 2026-11
- **Final completion:** 2028-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Decision based on no enrollment
- **Last updated:** 2024-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05574504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05574504, "Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05574504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*